Sutetinib Maleate Capsule Study is designed to help patients with advanced or spreading non-small cell lung cancer (NSCLC) with specific EGFR mutations. Sutetinib is a new drug that blocks EGFR, a gene that helps cells grow. Sometimes, this gene changes and causes cancer to grow and spread. This study tests how well the drug works and how safe it is.

Eligibility: Adults 18+ with confirmed advanced or spreading NSCLC and uncommon EGFR mutations may join. Participants must have a life expectancy of more than 3 months and be in good enough health. Those who have used certain cancer treatments recently or have unresolved severe health issues cannot participate.

• The study involves taking sutetinib capsules.
• Participants will be monitored for safety and effectiveness.
• There are specific criteria to determine if you can join the study.

Before joining, consider the study's requirements and your health. Talk to your healthcare provider to see if this study is a good fit for you.